Who is sponsoring NCT00690443?

NCT00690443 is sponsored by Aegerion Pharmaceuticals, Inc..

What condition does NCT00690443 study?

NCT00690443 studies Hypercholesterolemia.

What drugs are being tested in NCT00690443?

Interventions: Atorvastatin, AEGR-733.

What is the status of NCT00690443?

NCT00690443 is currently COMPLETED.

Last reviewed 2018-02-21 · How we verify

A Randomized, Double Blind Comparator-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of the Combination of AEGR-733 and Atorvastatin 20 mg vs Atorvastatin Monotherapy in Subjects With Moderate Hypercholesterolemia

NCT00690443 Phase 2 COMPLETED Results posted

Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.

Details

Lead sponsor	Aegerion Pharmaceuticals, Inc.
Phase	Phase 2
Status	COMPLETED
Enrolment	44
Start date	2008-05
Completion	2008-09

Conditions

Hypercholesterolemia

Interventions

Atorvastatin
AEGR-733

Primary outcomes

Percent Change in LDL-C After 8 Weeks of Therapy — Baseline and 8 weeks of treatment

Countries

United States